Tag: Repaglinide

According to the CDC, approximately 1 in 10 Americans has diabetes, and many require medication to manage their blood sugar levels. Among these, meglitinides are a unique class of drugs used for type 2 diabetes. The action of the meglitinides involves stimulating a rapid, short-lived burst of insulin from the pancreas to manage post-meal glucose spikes.

In some studies, post-prandial hyperglycemia (high blood sugar after meals) was recorded at least once in 84% of patients with otherwise well-controlled type 2 diabetes. For these individuals, knowing **when should meglitinides be administered** is critical for managing these glucose spikes.

Both meglitinides and sulfonylureas are a class of oral medications for type 2 diabetes that stimulate insulin release from the pancreas by acting on ATP-sensitive potassium channels. However, the key difference between meglitinides and sulfonylureas lies in their specific binding sites, pharmacokinetics (onset and duration of action), dosing schedule, and associated risk of hypoglycemia.

Over 38 million Americans have diabetes, with 90-95% of them having type 2 diabetes [1.9.1]. For many, oral medications are a key part of management. This raises a common question for patients and clinicians: **which is better, glipizide or repaglinide**, for controlling blood sugar?

According to the American Diabetes Association, meglitinides are one class of oral medications prescribed to help manage blood sugar levels in adults with type 2 diabetes. This rapid-acting group of drugs includes specific agents like nateglinide and repaglinide, which work by stimulating the pancreas to release insulin in response to a meal.